In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
The independent financial analyst theScreener just lowered the general evaluation of ENANTA PHARMACEUTICALS (US), active in the Health Care Providers industry. As regards its fundamental valuation, the title now shows 2 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date December 3, 2021, the closing pric...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
TTD currently trades above corporate averages relative to UAFRS-based (Uniform) earnings, with a 35.7x Uniform P/E. However, even at these levels, the market is pricing in expectations for Uniform ROA to collapse from 31% in 2019 to 6% in 2024, accompanied by 62% Uniform asset growth going forward. Meanwhile, analysts have similar expectations, projecting Uniform ROA to fade to 20% by 2021, accompanied by 28% Uniform asset growth. That said, management is confident about their consistent EBITDA ...
ï€ Enanta Pharmaceuticals, Inc. (ENTA:USA) currently trades below historical averages relative to UAFRS-based (Uniform) assets, with a 1.4x Uniform P/B. At these levels, the market has bearish expectations for the firm, and management may be concerned about their RSVP study, EDP-297, and EDP-514 ï€ Specifically, management may have concerns about the success of their RSVP study on RSV progress and symptoms and the success of EDP-938's Phase 2 study for pediatric patients. In addition, they ma...
AXL currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with an 11.9x Uniform P/E (Fwd V/E′). At these levels, the market is pricing in expectations for Uniform ROA to fade from 17% in 2018 to 5% in 2023, accompanied by 4% Uniform Asset growth going forward. Analysts have similar expectations, projecting Uniform ROA to fade to 10% in 2020, accompanied by 1% Uniform Asset shrinkage. Meanwhile, management is confident about their margins, sales, and cost managem...
Enanta Pharmaceuticals, Inc. (ENTA:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with an 18.9x Uniform P/E. At these levels, the market has bearish expectations for the firm, and management may be concerned about net income, R&D costs, and their pipeline. Specifically, management may lack confidence in their ability to initiate their first Phase IIb study for EDP-938 during 2019, and they may be concerned about the effectiveness of their EDP-514 comp...
Key Points: • Health Care Equipment & Supplies remains a leadership area in the Health Care Sector. • A number of Biotechnology stocks are making major reversals with many hitting 52-week RS highs. • Semiconductors, Semi-Suppliers, and Electronic Components remain as leadership Groups.
Summary Marketline's Achillion Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Achillion Pharmaceuticals, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensiv...
Key Points: • A number of Auto Component suppliers are showing signs of possible bottoms and reversals. • Offshore oil drillers continue to develop positively. Long-term trends are attractive. • The industrial Manufacturing Sector is increasingly showing positive inflections. • Communication equipment and electronic component suppliers continue to develop positively.
Key Points: • Biotechs are breaking out. XBI and IBB ETF's are bullish. • Homebuilders appear to be staging near-term reversals in price and RS. • Railroads continue to lead in the Transportation Sector. Many truckers are reversing near-term downtrends. • A few Consumer Staples equities are staging price and RS reversals. (Example POST)
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal second quarter ended March 31, 2018. Enanta’s results for the quarter benefited from $44 million of royalty revenue on AbbVie’s $919 million in sales of its HCV regimens that contain either of the two protease inhibitor products developed through Enanta’s collab...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.